Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy.
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Galinpepimut S (Primary) ; Montanide ISA-51; Sargramostim
- Indications Mesothelioma
- Focus Therapeutic Use
- 08 Aug 2017 According to a joint media release by Galena Biopharma Inc. and SELLAS Life Sciences Group Ltd., status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 04 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History